Diffuse Large B-cell Lymphoma
 | Improving the Spectrum of Care for Patients with Diffuse Large B-cell Lymphoma CME, CPE, CNE James O. Armitage, MD; John P. Leonard, MD; and Jason Westin, MD, MS, FACP | |
| Release Date: November 30, 2022 Expiration Date: November 30, 2023 | ||
In this activity, three experts discuss the spectrum of care for patients with diffuse large B-cell lymphoma (DLBCL). Dr. Armitage will begin by reviewing the history of treatment advances and the new classification of DLBCL. Dr. Leonard will discuss current data regarding investigational frontline therapies. Lastly, Dr. Westin will describe new targets and novel therapies in relapsed/refractory disease and beyond. This program concludes with an in-depth discussion on applying this information to current practice. Provided by MediCom Worldwide, Inc.This activity is supported by educational grants from Bristol Myers Squibb and Genentech, a member of the Roche Group. | ||
| Begin, Earn CreditView Only, No Credit | ||
 | New Directions in the Frontline Treatment of DLBCL: Implications for Practice CME, CPE James O. Armitage, MD; and Andrew D. Zelenetz, MD, PhD | |
| Release Date: November 09, 2022 Expiration Date: November 09, 2023 | ||
In this activity, Dr. Zelenetz will address current and emerging approaches in the frontline treatment of diffuse large b-cell lymphoma (DLBCL), he will also discuss current and potential practice implications. To conclude, Dr. Armitage and Dr. Zelenetz discuss how to apply these therapies to practice and look to future changes which may impact overall patient outcomes. Provided by MediCom Worldwide, Inc.This activity is supported by educational grants from Bristol Myers Squibb and Genentech, a member of the Roche Group. | ||
| Begin, Earn CreditView Only, No Credit | ||
 | New Directions in the Treatment of Relapsed/Refractory DLBCL: Implications for Practice CME, CPE James O. Armitage, MD; and Matthew Lunning, DO, FACP | |
| Release Date: October 28, 2022 Expiration Date: October 28, 2023 | ||
In this activity, Dr. Lunning will address key data from recent publications and conferences on current and emerging approaches for the treatment of relapsed/refractory DLBCL. To conclude, Dr. Armitage and Dr. Lunning will discuss current and potential practice implications. Provided by MediCom Worldwide, Inc.This activity is supported by educational grants from Bristol Myers Squibb and Genentech, a member of the Roche Group. | ||
| Begin, Earn CreditView Only, No Credit | ||
 | Addressing Disparities in Care for Patients with DLBCL CME, CPE James O. Armitage, MD; and Loretta J. Nastoupil, MD | |
| Release Date: September 21, 2022 Expiration Date: September 21, 2023 | ||
Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma. In this activity, two experts discuss disparities in care for patients with DLBCL. They will address topics such as barriers in care, participation in clinical trials, and improved treatment landscape. This activity will conclude with a discussion on tools to use for best practice. Provided by MediCom Worldwide, Inc.This activity is supported by educational grants from Bristol Myers Squibb and Genentech, a member of the Roche Group. | ||
| Begin, Earn CreditView Only, No Credit | ||